Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-Randomized Phase II Study of De-escalated Neoadjuvant Chemotherapy With Paclitaxel, Trastuzumab, and Pertuzumab (THP) Compared to Standard Regimen (TCHP) in Patients With Early HER2-Positive Breast Cancer

NCT07421141 is registered in ClinicalTrials.gov with National Medical Research Radiological Centre of the Ministry of Health of Russia as lead sponsor.

NCT NCT07421141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07421141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-Randomized Phase II Study of De-escalated Neoadjuvant Chemotherapy With Paclitaxel, Trastuzumab, and Pertuzumab (THP) Compared to Standard Regimen (TCHP) in Patients With Early HER2-Positive Breast Cancer
Lead sponsor
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 1, 2023
Completion date
December 30, 2028
Enrollment
186 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, early breast cancer, her2-positive breast cancer